# Diabetes Research Hub — Daily Iteration Report
**Date:** 2026-05-03 (Sunday)
**Run:** Automated agent #22

## Work queue items processed (5/16)

### 1. Vetted 12 papers — all VETTED, none flagged
| PMID | Source | Verdict |
|------|--------|---------|
| 40272935 | Roman et al, Diabetes 2025 | Mechanistic GKA paper (dorzagliatin vs MK-0941, X-ray crystallography). On-topic. |
| 40366501 | Dickens, Curr Diab Rep 2025 | Disparities in diabetes in pregnancy review. On-topic. |
| 40464081 | McEwan & Evans, Diabetes Obes Metab 2025 | Insulin health-economics review. On-topic. |
| 40544428 | Reichman/Markmann/Odorico, **NEJM 2025** | Zimislecel (VX-880) phase 1-2 stem-cell-derived islet trial. Real PMID; primary endpoint reported as freedom from severe hypoglycemia + HbA1c<7%. Not framed as "cure." On-topic. |
| 40573322 | Jin et al, Pharmaceuticals 2025 | Dorzagliatin for PI3Kα-inhibitor hyperglycemia (preclinical mice). On-topic. |
| 40598585 | **BMC Med 2025** | Systematic review + NMA of T1D immunotherapies (60 trials, 4,597 pts; 11/42 interventions improved C-peptide vs placebo). HIGH-VALUE — flagged for evidence extraction. |
| 40650745 | Degroote et al, Diabetologia 2025 | Verapamil + low-dose mATG in NOD mice (45% durable reversal at d56 vs 20%/17% monotherapy). PRECLINICAL — frame as proof-of-concept only. |
| 40737658 | Elebaid et al, Georgian Med News 2025 | LADA prevalence in Port Sudan (10.7% of insulin-treated T2D). Smaller-tier journal but methods sound. |
| 40814306 | Underwood et al, J Health Equity 2025 | PRISMA-Equity systematic review of CGM/pump disparities 2017–2024. On-topic. |
| 41468096 | Imam et al, Diabetes Technol Ther 2025 | GAD65-CAR-Tregs ex vivo + 30-day humanized mouse trial. PRECLINICAL only. |
| 41567805 | Zhou et al, Front Endocrinol 2025 | Treg dysfunction & engineered Treg therapies review. |
| 41618067 | Grzybowski & Jin, Ophthalmol Ther 2026 | Scoping review of 13 CE-certified AI DR-screening devices in EU. On-topic. |

### 2. Validated path: rituximab → nephropathy = **CONTRADICTED for diabetic nephropathy**
- Original path was a co-occurrence artifact from PMID 19940299 (Pescovitz NEJM 2009 — rituximab in T1D); "diabetic nephropathy" appeared in the paper only as a T1D complication, not as a treatment indication.
- Web validation: rituximab IS validated for *membranous* nephropathy (PMID 35074299: meta-analysis of 11 trials, n=723, significant remission improvement) — but membranous nephropathy is a distinct, autoimmune-mediated glomerular disease. Multiple membranous nephropathy trials explicitly EXCLUDE diabetic patients to avoid confounding.
- No RCT or systematic review supports rituximab in diabetic kidney disease.
- **Action queued:** rebuild research_paths.json to drop or rename this path; audit drug-repurposing dashboard for any rituximab+DKD claims (none currently exist in the build scripts — verified via grep).

### 3. Ingested 3 new abstracts → paper_library now 263 papers
- **41935855** — Subclinical carotid atherosclerosis in LADA vs T2DM (NMCD 2026; n=202 LADA vs 206 T2DM matched on age/sex/BMI/HbA1c/statins; LADA had lower IMT, BP, lipids, albuminuria).
- **41994768** — SGLT2i across the glycemic spectrum: CV/renal outcomes (Cureus 2026 narrative review; lower-tier journal — treat as background).
- **40598585** — BMC Med 2025 systematic review + NMA of T1D immunotherapies. **HIGH-VALUE.**

### 4. Credibility sweep — clean
- No fabricated PMIDs (>42M) found in any script.
- No "zero SAEs" / "zero rejection" / "100% protected" claims found in scripts.
- "Cure"/"curative" mentions all properly contextualized as preclinical category labels (e.g., dashboard category headers, BRONZE-tier explicitly tagged).
- `python3 Analysis/Scripts/run_quality_improvements.py` — **41/41 [OK]**.

### 5. State updated, but commit/push BLOCKED
- agent_state.json: 251 VETTED, 12 FLAGGED, 8 UNVETTED (was 239/12/20 at start).
- run_history now 22 entries.
- Queue size 16 (added: extract_evidence for 40598585; rebuild_research_paths to drop rituximab→nephropathy artifact; audit_dashboard for rituximab+DKD; next vet_papers_batch of 8).

## BLOCKER for user (now P1 in queue)
Stale `.git/index.lock`, `.git/HEAD.lock`, and `.git/objects/maintenance.lock` files remain. Workspace cannot remove them ("Operation not permitted"). Branch is **3 commits ahead of origin/main** and has uncommitted changes from the last several daily runs.

**Manual fix from PowerShell in the repo root:**
```powershell
Remove-Item .git\index.lock, .git\HEAD.lock, .git\objects\maintenance.lock
git push
```

## Cumulative progress
- 251/271 papers vetted (92.6%); on track to clear remaining 8 within 1–2 runs.
- 22 daily runs completed.
